<DOC>
	<DOCNO>NCT00468767</DOCNO>
	<brief_summary>This study conduct demonstrate effectiveness RSD1235 conversion atrial fibrillation sinus rhythm .</brief_summary>
	<brief_title>Phase III Tolerance Efficacy Study RSD1235 Patients With Atrial Fibrillation</brief_title>
	<detailed_description>There approximately 2 million report prevalent case atrial fibrillation ( AF ) atrial flutter United States ( Heart Disease &amp; Stroke Statistics - 2003 Update , AHA ) . These arrhythmia may occasional sustain . While directly fatal , arrhythmias cause discomfort lead stroke congestive heart failure . This Phase III trial Cardiome 's first pivotal study RSD1235 . The study seek confirm finding Phase II proof-of-concept demonstration RSD1235 's ability convert AF sinus rhythm . The patient population include recent onset AF ( AF duration 3 hour 7 day ) patient longer AF duration . This double-blind , placebo-controlled , randomized study patient AF ; stratification base duration AF . Treatment consider successful treatment-induced conversion atrial arrhythmia sinus rhythm minimum 1-minute Hour 1.5 ( Time 0 = start first infusion ) . All patient evaluate safety .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>18 year age old ; Have atrial arrhythmia symptom sustain great 3 hour 45 day . Have adequate anticoagulant therapy . Have QRS &gt; 0.14 second unless patient pacemaker uncorrected QT &gt; 0.440 second measure 12lead ECG . Have serious diseases/illnesses could interfere conduct validity study compromise patient safety . Have receive intravenous Class I Class III antiarrhythmic drug intravenous amiodarone within 24 hour prior dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Atrial fibrillation</keyword>
	<keyword>RSD1235</keyword>
	<keyword>Atrial fibrillation 3 hour 7 day duration .</keyword>
	<keyword>Atrial fibrillation 3 hour 45 day duration .</keyword>
</DOC>